Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
This multinational, double-blind, randomized, placebo-controlled, phase III trial assessed the efficacy and tolerability of the oral platinum analog satraplatin in patients with metastatic castrate-refractory prostate cancer (CRPC) experiencing progression after one prior chemotherapy regimen.
|Number of pages||8|
|Journal||Journal of Clinical Oncology|
|Publication status||Published - 2009|